Drug cuts incidence of cytomegalovirus after hematopoietic stem cell transplantation

05/8/2014 | Healio (free registration)

Patients who received the drug letermovir after hematopoietic stem cell transplantation had fewer cytomegalovirus infections than those who received a placebo, according to a study in The New England Journal of Medicine. All-cause prophylaxis failure was low and infections were detected sooner among study participants who received the highest doses.

View Full Article in:

Healio (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN